Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy

Leukemia

Volumn 26, Issue 4, 2012, Pages 839-841

  Sinha, S ^a   Lacy, M ^a   Mikhael, J ^b   Hayman, S ^a   Buadi, F ^a   Detweiler Short, K ^a   Dispenzieri, A ^a   Gertz, M ^a   Dingli, D ^a   Rajkumar, S V ^a   Kumar, S K ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; THALIDOMIDE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CHI SQUARE TEST; CHROMOSOME 17P; CHROMOSOME DELETION; DIPLOIDY; DISEASE COURSE; FISHER EXACT TEST; HUMAN; INSTITUTIONAL REVIEW; KAPLAN MEIER METHOD; KRUSKAL WALLIS TEST; LETTER; LOG RANK TEST; LOW DRUG DOSE; MEDICAL RECORD REVIEW; METAPHASE; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANK SUM TEST; SALVAGE THERAPY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; SALVAGE THERAPY; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84859646589     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.279     Document Type: Letter

References (14)

1. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009; 84: 1095-1110.
2. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
3. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617. (Pubitemid 36741588)
4. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111: 2962-2972.
5. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22: 3269-3276. (Pubitemid 41103682)
6. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008; 141: 41-51. (Pubitemid 351350609)
7. LacyMQ, Hayman SR, GertzMA, Dispenzieri A, Buadi F, Kumar S et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27: 5008-5014.
8. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010; 24: 1934-1939.
9. Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Sullivan D et al. A Phase 1/2 Multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. ASH AnnuMeet Abstr 2010; 116: 864.
10. Leleu X, Attal M, Moreau P, Duhamel A, Fermand JP, Michalet M et al. Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02. ASH Annu Meet Abstr 2010; 116: 859.
11. Lacy M, Mandrekar S, Gertz MAA, Hayman SR, Short KD, Buadi F et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. ASH Annu Meet Abstr 2010; 116: 863.
12. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2011; doi: 10.1038/leu.2011.196.
13. Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol 2009; 84: 657-660.
14. Madan S, Lacy M, Dispenzieri A, Gertz M, Buadi F, Hayman SR et al. Efficacy of retreatment with immunomodulatory compounds in patients receiving initial therapy for newly diagnosed multiple myeloma. ASH Annu Meet Abstr 2010; 116: 1964.